$AMLX

Amylyx Pharmaceuticals (AMLX) surged 63% after reporting positive Phase 3 trial results for avexitide, with Stifel doubling its price target to $45. Iovance Biotherapeutics (IOVA) hit a 52-week high, driven by Q2 earnings and a price target increase from Mizuho. ONEOK (OKE) reached a 52-week high following strong Q2 earnings, raised 2026 guidance, and a new supply deal, with Morgan Stanley raising its target to $105.

Amylyx Pharmaceuticals (AMLX) shares rose 47% after reporting positive Phase 3 trial results for Avexitide, a treatment for post-bariatric hypoglycemia. The drug met primary and secondary endpoints, with plans for FDA submission by 2026. AMLX expects cash to fund operations into 2028, covering a potential 2027 launch. Retail sentiment turned bullish, with some predicting a 70% upside.

Amylyx Pharmaceuticals (AMLX) shares rose after reporting positive Phase 3 trial results for avexitide, its GLP-1 treatment for post-bariatric hypoglycemia. The drug showed a 55% reduction in severe hypoglycemic events and a favorable safety profile. The company plans to submit an NDA to the FDA by year-end.

Amylyx Pharmaceuticals' stock surged nearly 79% after positive Phase 3 trial results for avexitide, a drug targeting post-bariatric hypoglycemia. The company also announced a $500 million secondary stock offering. Analysts raised price targets, with Guggenheim's Seamus Fernandez setting a new target of $55 per share. The stock closed at $38.66, giving the company a market cap of $4.4 billion.

Amylyx Pharmaceuticals (AMLX) released Phase 3 LUCIDITY trial results for avexitide, a treatment for post-bariatric hypoglycemia. Shares rose 15.7% after-hours. The trial's success could validate Amylyx's shift to endocrine disease, while failure may refocus attention on earlier-stage programs. The company has $250.8M in cash, sufficient until 2028. Avexitide has Breakthrough Therapy designation, with a potential 2027 launch if approved.

Mizuho named Amylyx Pharmaceuticals a top small/midcap biotech pick, raising its price target 40% to $42 after positive Phase 3 trial results for avexitide. Guggenheim and H.C. Wainwright also raised targets to $55. The company aims for US regulatory filing by 2026 and potential 2027 launch.

Amylyx (AMLX) reported a 55% reduction in severe post-bariatric hypoglycemia events in its Phase 3 LUCIDITY trial of avexitide. The company plans to submit avexitide for FDA approval by the end of 2026. AMLX also filed an offering to sell 14.09M shares at $35.50, aiming to raise ~$471.7M for avexitide's U.S. launch, manufacturing, and R&D.

Iovance Biotherapeutics (IOVA) surged 12% to a 52-week high after reporting Q2 revenue of $99.3M and a UBS price target raise. Amylyx Pharmaceuticals (AMLX) rose 2% on positive Phase 3 trial results and a $500M offering. ConocoPhillips (COP) gained 3% after strong Q2 earnings and a Morgan Stanley price target increase.

Amylyx Pharmaceuticals, Inc. (AMLX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 19, 2026, Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LL

Amylyx Pharmaceuticals priced a $500 million upsized public offering of common stock. The company increased the offering size from the initially announced $400 million. The offering is expected to close on or about May 24, 2023, subject to customary closing conditions, according to the company.